Literature DB >> 21270075

Electrocardiographic changes in early recognition of Fabry disease.

Mehdi Namdar1, Jan Steffel, Mile Vidovic, Corinna B Brunckhorst, Johannes Holzmeister, Thomas F Lüscher, Rolf Jenni, Firat Duru.   

Abstract

BACKGROUND: Fabry disease (FD) is an inherited X-chromosomal lysosomal storage disease resulting in intracellular storage of globotriaosylceramide. Cardiac involvement is most frequently manifested as left ventricular hypertrophy (LVH). However, patients with FD may also have various conduction abnormalities before LVH develops. The present study was designed to analyse early conduction abnormalities on baseline ECG of patients with FD and to investigate their diagnostic value. METHODS AND
RESULTS: Baseline electrocardiographic (ECG) and echocardiographic measurements of patients with FD (n = 30) were compared with those of heart rate and age-matched healthy individuals (n = 50). The PQ-interval (131 ± 18 vs 155 ± 20 ms, p < 0.000001) and the QRS width (83 ± 11 vs 90 ± 9 ms, p < 0.05) were significantly shorter and repolarisation dispersion was more pronounced in patients with FD (QTc dispersion: 66 ± 32 vs 40 ± 24 ms, p < 0.001, T(peak)-T(end) dispersion: 56 ± 20 vs 37 ± 16 ms, p < 0.0005). Moreover, P-wave duration was significantly shorter (74 ± 16 vs 105 ± 14 ms, p < 0.000001) in FD and accounted predominantly for the shortening of the PQ-interval. P-wave duration showed a 92% sensitivity and 80% specificity for the diagnosis of FD.
CONCLUSIONS: P-wave duration, PQ-interval and QRS width are shorter and repolarisation dispersion more pronounced in patients with FD compared with heart rate and age-matched controls. The significant shortening of the PQ-interval in FD occurs because of a marked shortening of the P-wave duration, which in itself demonstrated a high sensitivity and specificity for early detection and treatment of this disease.

Entities:  

Mesh:

Year:  2011        PMID: 21270075     DOI: 10.1136/hrt.2010.211789

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  20 in total

Review 1.  Left ventricular hypertrophy: The relationship between the electrocardiogram and cardiovascular magnetic resonance imaging.

Authors:  Ljuba Bacharova; Martin Ugander
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-11-04       Impact factor: 1.468

2.  Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease.

Authors:  Massimo Imbriaco; Teresa Pellegrino; Valentina Piscopo; Mario Petretta; Andrea Ponsiglione; Carmela Nappi; Marta Puglia; Serena Dell'Aversana; Eleonora Riccio; Letizia Spinelli; Antonio Pisani; Alberto Cuocolo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-22       Impact factor: 9.236

3.  Cross-sectional baseline analysis of electrocardiography in a large cohort of patients with untreated Fabry disease.

Authors:  Markus Niemann; Tanja Hartmann; Mehdi Namdar; Frank Breunig; Meinrad Beer; Wolfram Machann; Sebastian Herrmann; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

Review 4.  Fabry disease.

Authors:  Toshinori Yuasa; Toshihiro Takenaka; Koji Higuchi; Nami Uchiyama; Yoshihisa Horizoe; Hideto Cyaen; Naoko Mizukami; Kunitsugu Takasaki; Akira Kisanuki; Masaaki Miyata; Mitsuru Ohishi
Journal:  J Echocardiogr       Date:  2017-07-03

5.  Early cardiac changes in children with anderson-fabry disease.

Authors:  Stepan Havranek; Ales Linhart; Zuzana Urbanova; Uma Ramaswami
Journal:  JIMD Rep       Date:  2013-04-02

6.  Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes.

Authors:  Ja Hye Kim; Beom Hee Lee; Ja Hyang Cho; Eungu Kang; Jin-Ho Choi; Gu-Hwan Kim; Han-Wook Yoo
Journal:  J Hum Genet       Date:  2016-06-23       Impact factor: 3.172

Review 7.  2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease.

Authors:  Chung-Lieh Hung; Yen-Wen Wu; Chih-Chan Lin; Chih-Hung Lai; Jimmy Jyh-Ming Juang; Ting-Hsing Chao; Ling Kuo; Kuo-Tzu Sung; Chao-Yung Wang; Chun-Li Wang; Chun-Yuan Chu; Wen-Chung Yu; Charles Jia-Yin Hou
Journal:  Acta Cardiol Sin       Date:  2021-07       Impact factor: 2.672

8.  Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis.

Authors:  Jiwon Seo; Minji Kim; Geu-Ru Hong; Dae-Seong Kim; Jang-Won Son; In Jeong Cho; Chi Young Shim; Hyuk-Jae Chang; Jong-Won Ha; Namsik Chung
Journal:  J Hum Genet       Date:  2016-05-26       Impact factor: 3.172

9.  Electrical Changes in Resting, Exercise, and Holter Electrocardiography in Fabry Cardiomyopathy.

Authors:  Johannes Krämer; Peter Nordbeck; Stefan Störk; Christian Ritter; Georg Ertl; Christoph Wanner; Frank Weidemann
Journal:  JIMD Rep       Date:  2015-10-27

Review 10.  Deciphering hypertrophic cardiomyopathy with electrocardiography.

Authors:  Thomas Gossios; Konstantinos Savvatis; Thomas Zegkos; Dimitrios Ntelios; Pavlos Rouskas; Despoina Parcharidou; Haralambos Karvounis; Georgios K Efthimiadis
Journal:  Heart Fail Rev       Date:  2021-07-21       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.